Patient-centricity has become a core operational priority in pharma, driven by regulatory expectations and patient demand for active participation in treatment development. The article highlights how Virtual Advisory Boards (VABs) revolutionize engagement by transforming fragmented data collection into ongoing, inclusive dialogue between patients and pharma, ensuring decisions reflect real-world experiences. By leveraging secure digital platforms like MphaR’s Virtual Advisory Board, companies can achieve scalable, compliant, and truly patient-centered collaboration that enhances trust, outcomes, and regulatory alignment.